Clinical trial
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06028230 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 29, 2023
- Completion date
- November 12, 2025
- Enrollment
- 70 (actual)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.